BD (Becton, Dickinson and Company): FDA 510(k) clearances across all its applicant names
FDA lists 1,961 510(k) clearances, 17 PMA and 0 De Novo decisions across the 46 applicant names Caduvo groups under BD (Becton, Dickinson and Company), first 1976, latest 2026. Median 510(k) review time across these names: 65 days. Since 2017 the median was 128 days, against 134 days for all cleared 510(k)s in the same product codes. Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 28 | 88 |
| 2013 | 35 | 71 |
| 2014 | 30 | 85 |
| 2015 | 32 | 108 |
| 2016 | 44 | 110 |
| 2017 | 33 | 90 |
| 2018 | 20 | 110 |
| 2019 | 18 | 122 |
| 2020 | 17 | 110 |
| 2021 | 20 | 121 |
| 2022 | 24 | 171 |
| 2023 | 24 | 165 |
| 2024 | 14 | 122 |
| 2025 | 33 | 130 |
| 2026 | 17 | 162 |
The 46 FDA applicant names in this group
| Applicant name | 510(k) clearances | PMA | De Novo | Years |
|---|---|---|---|---|
| C.R. Bard, Inc. | 655 | 5 | 0 | 1976–2026 |
| Bd Becton Dickinson Vacutainer Systems Preanalytic | 632 | 2 | 0 | 1976–2001 |
| Becton, Dickinson & CO | 341 | 1 | 0 | 2001–2026 |
| Davol, Inc. | 50 | 1 | 0 | 1977–2025 |
| Bard Peripheral Vascular, Inc. | 39 | 7 | 0 | 2003–2026 |
| Becton Dickinson Infusion Therapy Systems, Inc. | 36 | 0 | 0 | 1997–2026 |
| Becton Dickinson Vascular Access, Inc. | 25 | 0 | 0 | 1992–1997 |
| Davol Inc., Sub. C. R. Bard, Inc. | 24 | 1 | 0 | 1994–2010 |
| Bard Access Systems, Inc. | 22 | 0 | 0 | 1993–2025 |
| Alaris Medical Systems, Inc. | 16 | 0 | 0 | 1998–2004 |
| Bd | 15 | 0 | 0 | 2001–2026 |
| Becton Dickinson Vacutainer Systems | 15 | 0 | 0 | 1995–2000 |
| Carefusion 2200, Inc. | 14 | 0 | 0 | 2009–2021 |
| Cardinal Health, Alaris Products | 9 | 0 | 0 | 2005–2007 |
| Cormed, Inc., Sub. C.R.Bard, Inc. | 8 | 0 | 0 | 1983–1986 |
| Carefusion 303, Inc. | 7 | 0 | 0 | 2011–2025 |
| Becton, Dickinson and Company (BD) | 5 | 0 | 0 | 2009–2026 |
| Cardinal Health 303,Inc. | 4 | 0 | 0 | 2006–2009 |
| Davol Inc., Subsidiary of C. R. Bard, Inc. | 4 | 0 | 0 | 2019–2025 |
| Bard Access Systems, Inc. (C.R. Bard, Inc.) | 3 | 0 | 0 | 2021–2024 |
| Bard Cardiosurgery Div | 3 | 0 | 0 | 1989–1992 |
| Bard Medical Div. | 3 | 0 | 0 | 1997–1999 |
| Carefusion, Inc. | 3 | 0 | 0 | 2016–2020 |
| Bard Access Systems, Inc. (Bard Has Joined Bd) | 2 | 0 | 0 | 2019–2020 |
| Bard Interventional Products Div. | 2 | 0 | 0 | 1996–1998 |
| Bd Vacutainer Systems Preanalyical Solutions | 2 | 0 | 0 | 2002–2003 |
| Davol, Inc., A Subsidiary of C.R. Bard, Inc. | 2 | 0 | 0 | 2025–2026 |
| Pilot Cardiovascular Systems, Inc., Sub. C.R. Bard | 2 | 0 | 0 | 1992–1993 |
| Bard Access Systems, Inc(Bas)[Wholly-Owned Subsidiary of Bd] | 1 | 0 | 0 | 2021–2021 |
| Bard Electro Medical Systems, Inc. | 1 | 0 | 0 | 1988–1988 |
| Bard Gynecology and Radiology | 1 | 0 | 0 | 1994–1994 |
| Bard Medsystems Div. | 1 | 0 | 0 | 1993–1993 |
| Bard Peripheral Vacular, Inc. | 1 | 0 | 0 | 2016–2016 |
| Bard Reproductive Systems | 1 | 0 | 0 | 1994–1994 |
| Bd Medical-Medical Surgical Systems | 1 | 0 | 0 | 2012–2012 |
| Bd Medical Surgical | 1 | 0 | 0 | 2011–2011 |
| Bd Medical Systems | 1 | 0 | 0 | 2001–2001 |
| Bd/Preefil | 1 | 0 | 0 | 2000–2000 |
| Becton, Dickinson and Company (Bard Access Systems, Inc.) | 1 | 0 | 0 | 2024–2024 |
| Becton Dickinson Curlin, LLC | 1 | 0 | 0 | 1998–1998 |
| Becton Dickinson Inc. (Bd) | 1 | 0 | 0 | 2025–2025 |
| Becton Dickson & Co. | 1 | 0 | 0 | 2009–2009 |
| C B Bard, Inc. | 1 | 0 | 0 | 2021–2021 |
| C.R. Bard, Inc (Bard Has Joined Bd) | 1 | 0 | 0 | 2018–2018 |
| Carefusion (Bd) | 1 | 0 | 0 | 2025–2025 |
| Clay Adams, Div. Becton Dickinson & Co. | 1 | 0 | 0 | 1976–1976 |
Review time against the same product codes
Since 2017, 510(k)s cleared under these names took a median 128 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 134 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| LON | System, Test, Automated, Antimicrobial Susceptibility, Short Incubation | 124 | 123 |
| FOZ | Catheter, Intravascular, Therapeutic, Short-Term Less Than 30 Days | 79 | 79 |
| FRN | Pump, Infusion | 56 | 56 |
| JKA | Tubes, Vials, Systems, Serum Separators, Blood Collection | 56 | 56 |
| JTN | Susceptibility Test Discs, Antimicrobial | 55 | 55 |
| LJS | Catheter, Intravascular, Therapeutic, Long-Term Greater Than 30 Days | 50 | 50 |
| FMI | Needle, Hypodermic, Single Lumen | 48 | 48 |
| FMF | Syringe, Piston | 46 | 46 |
| FTL | Mesh, Surgical, Polymeric | 41 | 41 |
| JWY | Manual Antimicrobial Susceptibility Test Systems | 32 | 32 |
Plus 452 more product codes.
Review panels
- General Hospital (464)
- Microbiology (434)
- Cardiovascular (265)
- Gastroenterology and Urology (222)
- Clinical Chemistry (185)
- General and Plastic Surgery (167)
- Anesthesiology (60)
- Hematology (57)
- Obstetrics and Gynecology (31)
- Radiology (22)
- Clinical Toxicology (17)
- Orthopedic (13)
- Immunology (12)
- Pathology (6)
- Physical Medicine (6)
- Ear, Nose and Throat (2)
- Ophthalmic (2)
- Neurology (1)
Most recent BD (Becton, Dickinson and Company) 510(k) clearances
| 510(k) | Device | Applicant name | Product code | Decision date | Review days |
|---|---|---|---|---|---|
| K252344 | BD Vacutainer® Serum Blood Collection Tubes; BD Vacutainer® Rapid Serum Tubes (RST) | Becton, Dickinson & CO | JKA | 2026-10-16 | 445 |
| K261543 | Phasix ST Parastomal Hernia Mesh | Davol, Inc., A Subsidiary of C.R. Bard, Inc. | OWT | 2026-09-28 | 143 |
| K262163 | BD BBL Mueller Hinton II Broth (Cation-Adjusted); BD Difco Mueller Hinton Broth | Becton, Dickinson & CO | JTZ | 2026-09-14 | 80 |
| K262571 | EnCor EnCompass Breast Biopsy and Tissue Removal System | Bard Peripheral Vascular, Inc. | KNW | 2026-08-14 | 21 |
| K253514 | Minnesota Four-Lumen Esophagogastric Tamponade Tube - 18 French (0092220); Blakemore Esophageal-Nasogastric Tube - 20 French (0092100); Blakemore Esophageal-Nasogastric Tube - 16 French (0092300) | C.R. Bard, Inc. | KNT | 2026-07-10 | 246 |
| K254076 | BD Touchless Plus Unisex Pre-Lubricated Urethral Catheter Kit | C.R. Bard, Inc. | FCM | 2026-05-29 | 162 |
| K260128 | BD Preset and BD A-Line Arterial Blood Collection Syringes | Becton, Dickinson & CO | JKA | 2026-04-15 | 89 |
| K252506 | BD Vacutainer® Safety-Lok Blood Collection Set; BD Vacutainer® Safety-Lok Blood Collection Set with Pre-Attached Holder | Becton, Dickinson & CO | JKA | 2026-04-10 | 245 |
| K252378 | BD® MiniDraw Capillary Blood Collection System with BD® MiniDraw SST Capillary Blood Collection Tube | Becton, Dickinson & CO | JKA | 2026-04-10 | 254 |
| K260184 | Onclarity Self-Collection Kit | Becton, Dickinson & CO | SEP | 2026-04-02 | 71 |
1,951 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| P250050 | PMA | Liverty TIPS Stent Graft | 2026-09-25 |
| P180037 | PMA | Venovo Venous Stent System | 2019-03-13 |
| P170042 | PMA | Covera Vascular Covered Stent | 2018-07-30 |
| P160037 | PMA | BD ONCLARITY HPV ASSAY | 2018-02-12 |
| P160024 | PMA | LIFESTREAM BALLOON EXPANDABLE VASCULAR COVERED STENT | 2017-04-24 |
Recalls
1,408 product recalls in 566 recall events under these names; 427 initiated in the last five years.
356 product recalls in 101 recall events filed under other recalling-firm names cite a 510(k) or PMA held under these applicant names; 40 initiated in the last five years. Most often: Centurion Medical Products Corporation (35), C.R. Bard Access Systems, Inc (29), Zevex International, Inc. (25).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to the applicant names above by name only, so recalls filed under other names are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
ClinicalTrials.gov lists 150 device studies (15 active or recruiting) with an industry lead sponsor under the 2 sponsor names below. Most recent:
- NCT07798128: Evaluation of Catheter Utilization in Female Patients Using Indwelling Urinary Catheters and the PureWick™ Flex Female External Catheter (Becton, Dickinson and Company; Not yet recruiting, started 2026-11-06)
- NCT07744945: Evaluation of Male and Female External Catheters for Urine Output Monitoring in the ICU (C. R. Bard; Enrolling by invitation, started 2026-09-02)
- NCT06934486: Observational Study of TissuePatch SF in Prevention of Air Leaks Following Lung Resection (C. R. Bard; Not yet recruiting, started 2026-07-01)
- NCT07216573: The Continuity Study (Becton, Dickinson and Company; Recruiting, started 2026-05-07)
- NCT07555548: UK PureWick™ At-Home Pilot Study (Becton, Dickinson and Company; Recruiting, started 2026-05-06)
| Lead sponsor name on ClinicalTrials.gov | Device studies |
|---|---|
| C. R. Bard | 103 |
| Becton, Dickinson and Company | 47 |
Sponsor names are matched to the applicant names above by name, with punctuation and legal suffixes removed, plus sponsor names reviewed for this group. Studies listed under other sponsor names are not counted.
Parent company SEC filings
BECTON DICKINSON & CO (BDX): EDGAR filings, CIK 10795. The parent's SEC registrant is entered by hand for this group, not matched by name.
How this group is built
Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
C.R. Bard (December 2017; incl. Davol, Bard Access Systems, Bard Peripheral Vascular) and CareFusion (2015; incl. Alaris infusion, whose earlier filings were made under Cardinal Health 303 / Cardinal Health Alaris Products). Includes filings made before each acquisition. Left out: Biosciences and Diagnostic Solutions names (combined with Waters Corporation, February 9, 2026), Bard Electrophysiology (sold to Boston Scientific 2013), CareFusion respiratory names (Vyaire, 2016), BD consumer and diabetes names (Embecta, 2022). Edwards Critical Care (BD since September 2024) filed under Edwards Lifesciences and is not included. The plain BD / BECTON DICKINSON names still contain some pre-2026 diagnostics filings that cannot be split out.
Sources
- https://en.wikipedia.org/wiki/Becton_Dickinson
- https://en.wikipedia.org/wiki/C._R._Bard
- https://en.wikipedia.org/wiki/CareFusion
- https://investors.bd.com/news-events/press-releases/detail/937/bd-completes-combination-of-biosciences-diagnostic-solutions-business-with-waters-corporation
Frequently asked questions
How many FDA 510(k) clearances are listed across BD (Becton, Dickinson and Company)'s applicant names?
FDA lists 1,961 510(k) clearances, 17 PMA and 0 De Novo decisions across the 46 applicant names Caduvo groups under BD (Becton, Dickinson and Company), first 1976, latest 2026. FDA records each applicant name separately; Caduvo adds up the names listed on this page.
Which FDA applicant names does BD (Becton, Dickinson and Company) file under?
The names with the most 510(k) clearances in this group are C.R. Bard, Inc. (655); Bd Becton Dickinson Vacutainer Systems Preanalytic (632); Becton, Dickinson & CO (341); Davol, Inc. (50); Bard Peripheral Vascular, Inc. (39). The full list of 46 names is on this page.
How long does FDA take to clear BD (Becton, Dickinson and Company) 510(k)s?
The median time from FDA receipt to decision across 510(k)s cleared under these names is 65 days. Since 2017 the median was 128 days, against 134 days for all cleared 510(k)s in the same product codes.
Does the BD (Becton, Dickinson and Company) count include acquired companies?
Yes. A group includes filings an acquired business made under its own name, including before the acquisition. Businesses that were sold are left out, and names whose ownership is unclear are not included. FDA does not group applicants; the sources for each grouping are listed on this page.
How many device clinical trials does BD (Becton, Dickinson and Company) sponsor?
ClinicalTrials.gov lists 150 device studies (15 active or recruiting) with an industry lead sponsor under 2 sponsor names Caduvo groups under BD (Becton, Dickinson and Company). ClinicalTrials.gov names the sponsor on each study; Caduvo adds up the names listed on this page.
Next steps
- See all 1,961 BD (Becton, Dickinson and Company) clearances with predicates and recalls
- Run predicate analysis for product code LON, BD (Becton, Dickinson and Company)'s most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this grouping or data. Data and corrections policy.
All parent companies · FDA device companies by applicant name · FDA product code lookup